Discovery of novel thyrointegrin αvβ3 antagonist fb-PMT (NP751) in the management of human glioblastoma multiforme

BACKGROUND: Thyrointegrin αvβ3 receptors are unique molecular cancer therapeutic targets because of their overexpression on cancer and rapidly dividing blood vessel cells compared and quiescent on normal cells. A macromolecule, TriAzole Tetraiodothyroacetic acid (TAT) conjugated to polyethylene glyc...

Descripción completa

Detalles Bibliográficos
Autores principales: Godugu, Kavitha, Hay, Bruce A, Glinsky, Gennadi V, Mousa, Shaker A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Basic and Translational Investigations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9985163/
https://www.ncbi.nlm.nih.gov/pubmed/36879662
http://dx.doi.org/10.1093/noajnl/vdac180

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9985163/
https://www.ncbi.nlm.nih.gov/pubmed/36879662
http://dx.doi.org/10.1093/noajnl/vdac180

Ejemplares similares